Bullish indicating open at $55-$60, IPO prices at $37
Shirley R. Kuhlmann, Executive Vice President and General Counsel at Collegium Pharmaceutical , Inc. (NASDAQ:COLL), a pharmaceutical company with an impressive 86.77% gross profit margin and market capitalization of $939 million, recently executed significant stock transactions, according to a recent SEC filing. On March 4, Kuhlmann exercised options to acquire 40,000 shares of common stock at $24.03 per share. Subsequently, she sold 40,000 shares on the same day at a weighted average price of $28.0790, with prices ranging from $28.00 to $28.24.
The selling activity continued on March 5, with Kuhlmann disposing of an additional 20,000 shares at an average price of $28.0264, within a range of $28.00 to $28.18. On March 6, she sold 26,067 shares at an average price of $28.5014, with transactions ranging from $28.50 to $28.58. In total, these sales amounted to approximately $2.43 million.
Following these transactions, Kuhlmann’s direct ownership stands at 108,137 shares. For comprehensive insider trading analysis and additional insights, including 7 key ProTips and detailed valuation metrics, visit InvestingPro.
In other recent news, Collegium Pharmaceuticals reported its fourth-quarter 2024 earnings, surpassing analyst expectations with an earnings per share (EPS) of $1.75, compared to the forecast of $1.66. The company also exceeded revenue projections, posting $181.9 million against the anticipated $179.48 million. This reflects a 22% year-over-year increase in quarterly revenue. For the full year 2024, Collegium’s revenue reached $631.4 million, marking an 11% increase from the previous year. Analysts have noted the company’s strong operational execution and successful product strategies, particularly in its ADHD and pain management portfolios. Looking ahead, Collegium projects net product revenue between $735 million and $750 million for 2025, with adjusted EBITDA expected to grow by over 10%. The company plans to expand its sales force and invest in digital marketing to drive further growth, particularly for its ADHD medication, Jornay. Additionally, Collegium’s stock received positive guidance from analysts, reinforcing confidence in the company’s growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.